Eli Lilly and Company

LLYNYSE

$1,294.35

Last price · USD

Multiples use last price and FY2025 annual figures. Market cap estimated from diluted shares.

Eli Lilly and Company income statement

Annual · USD millions except per-share data · 27 lines

Fiscal year	2025latest	2024	2023	2022	2021	CAGR
Revenue & gross profit
Revenue	65,179	45,043	34,124	28,541	28,318	+23.2%
Cost of revenue	11,052	8,418	7,082	6,630	7,313	+10.9%
Gross profit	54,127	36,625	27,042	21,912	21,006	+26.7%
Operating expenses & income
Research & development	13,337	10,991	9,313	7,191	6,931	+17.8%
General & administrative	0	8,594	6,941	6,068	6,142	—
Selling & marketing	0	0	0	0	0	—
SG&A (combined)	11,094	8,594	6,941	6,068	6,142	+15.9%
Total operating expenses	24,431	19,585	16,255	13,258	13,073	+16.9%
Cost and expenses	35,483	28,003	23,337	19,888	20,385	+14.9%
Operating income	29,696	17,040	10,787	8,653	7,933	+39.1%
Non-operating & other
Interest income	153	175	174	63	25	+56.7%
Interest expense	795	781	486	332	340	+23.7%
Net interest income	(642)	(605)	(312)	(269)	(314)	—
Non-operating income (excl. interest)	0	0	3,747	1,515	1,438	—
Total other income (expenses), net	(3,965)	(4,360)	(4,233)	(1,847)	(1,777)	—
Profitability
Depreciation & amortization	1,997	1,767	1,527	1,523	1,548	+6.6%
Income before tax	25,731	12,680	6,555	6,806	6,156	+43.0%
Income tax expense	5,091	2,090	1,314	562	574	+72.6%
Net income from continuing operations	20,640	10,590	5,240	6,245	5,582	+38.7%
Net income	20,640	10,590	5,240	6,245	5,582	+38.7%
Bottom line net income	20,640	10,590	5,240	6,245	5,582	+38.7%
Additional fields
Ebit	29,696	17,040	7,041	7,138	6,495	+46.2%
Ebitda	31,693	18,807	8,568	8,661	8,043	+40.9%
Eps	$23.07	$11.76	$5.83	$6.57	$5.85	+40.9%
Eps Diluted	$22.95	$11.71	$5.80	$6.57	$5.85	+40.7%
Weighted Average Shs Out	898	901	899	950	954	-1.5%
Weighted Average Shs Out Dil	898	904	903	950	954	-1.5%